Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The proto-oncogene c-Myc plays a crucial role in cell proliferation, differentiation, and apoptosis.
• Targeting c-Myc in cancer cells is challenging due to its complex regulatory mechanisms.
• Overexpression of c-Myc is a hallmark of several aggressive cancers.

Purpose of the Study:

• To identify chemical compounds that selectively induce cell death in c-Myc-overexpressing cancer cells.
• To investigate the mechanism of action of a promising compound, C604.
• To evaluate the potential of C604 as a targeted therapeutic agent for c-Myc-driven cancers.

Main Methods:

• High-throughput screening of approximately 4000 chemical compounds using MTS assays.
• Treatment of c-Myc-overexpressing (STF-cMyc) and control (STF-Control) cells with identified compounds.
• Analysis of apoptotic markers, including caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage.
• Cell cycle analysis and assessment of protein accumulation (c-Myc, Cdc25A).

Main Results:

• Compound C604 selectively induced cell death in STF-cMyc cells but not in STF-Control cells.
• C604 treatment led to the cleavage of apoptotic proteins caspase-3 and PARP in c-Myc-overexpressing cells.
• C604 demonstrated efficacy in various cancer cell lines (SW620, HCT116, NCI-H23) with high basal c-Myc levels, inducing apoptotic cell death.
• C604 caused G2/M cell cycle arrest and accumulation of c-Myc and Cdc25A proteins, independent of apoptotic inhibitors.

Conclusions:

• A novel chemical compound, C604, has been identified as a selective inducer of apoptosis in cancer cells with c-Myc amplification.
• C604 targets cancer cells through an apoptotic pathway, offering a potential therapeutic strategy.
• Further investigation into C604's mechanism and efficacy is warranted for its development as a cancer therapeutic.